Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy
The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody... 
Via Benzinga
CureVac Outlines Upcoming Catalysts For Vaccine Programs
Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs. CureVac's preclinical second-... 
Via Benzinga
Market Briefing For Wednesday, Jan. 5
Rising interest rates have yet to spark overt action by the Fed nor yet to cool-off the hot real estate market. However, the Nasdaq was hit hard, presumably as the 10-year rallied. 
Via Talk Markets
Market Trend: Erratic And Unreliable
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is. 
Via Talk Markets
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
Via Benzinga
Pfizer's CEO Shows You How To Get 'Impossible' Tasks Done Fast
Scientists told the Pfizer CEO they could create a vaccine in 18 months. But Albert Bourla knew they could work even faster. 
Via Investor's Business Daily
A Bit Of Good News
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%. 
Via Talk Markets
GSK Option Bulls Get Head Start on Cup & Handle
Pharma has been one of the best performing industries in recent weeks and GlaxoSmithKline has been among the top performers. Today, it appears that call buyers are stepping into the stock as it tests... 
Via Talk Markets
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
Long-Acting HIV Treatment Backed By GSK, Pfizer Scores FDA Approval As Preventative Option
The FDA has approved ViiV Healthcare's Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option, to reduce the risk of... 
Via Benzinga
Dreaming Of A Red Christmas
The stock market is reacting with lots of selling to the weekend's news. 
Via Talk Markets
7 Stocks to Buy if Covid-19 Becomes Endemic
Watching the developments of the Covid-19 crisis, it could become endemic. Here’s what that means for certain stocks to buy. 
Via InvestorPlace
GlaxoSmithKline: Investing In Vaccines
GlaxoSmithKline, based in London, is a global healthcare company engaged in the discovery, development, manufacture, and marketing of pharmaceutical and consumer healthcare products. Let's take a look... 
Via Talk Markets
Glaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19
The European Commission (EC) has granted marketing authorization to GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR)... 
Via Benzinga
Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain
Two tests from independent labs suggest Adagio's antibody could still target omicron. 
Via Investor's Business Daily
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year.... 
Via Benzinga
Why Are Vir Biotech Shares Gaining Today?
Vir Biotechnology Inc (NASDAQ: VIR) announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic... 
Via Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
Omicron Surge
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969. 
Via Talk Markets
Wednesday Global Investing Report
Between the Amazon Cloud issues and the clouds gathering over the Ukraine border, it's getting harder to tell exactly what's happening to markets. Here are some insights into the international... 
Via Talk Markets
Market Briefing For Wednesday, Dec. 8
The surge extended and this time brought more small-caps along with what was a broad advance that is partially attributable to 'hopium' regarding reduced fears about COVID-Omicron. 
Via Talk Markets
Cramer Gives His Opinion On GlaxoSmithKline, Asana And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Penn National Gaming, Inc. (NASDAQ: 
Via Benzinga
Investors Do A Little Holiday Value Shopping On Monday
The Nasdaq futures were rallying nearly 2% before the open as technology stocks decide to follow the Dow Jones 30. Many stocks rallied on Monday as early data concerning the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not... 
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
Medicago, GSK's Plant-Based COVID-19 Vaccine Candidate Hits 75% Efficacy Against Delta Strain
Canada-based Medicago and GlaxoSmithKline plc (NYSE: GSK) have released Phase 3 data from their plant-derived adjuvanted COVID-19 vaccine candidate.... 
Via Benzinga
Exposures COVID-19
Preclinical Data Shows GSK-Vir COVID-19 Drug Works Against All Omicron Mutations
GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all... 
Via Benzinga
Exposures COVID-19
Charms Of China
Today the global stock market rout was pretty awful. 
Via Talk Markets
Why Jim Cramer Likes Enbridge, Vir Biotechnology And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enbridge Inc. (NYSE: 
Via Benzinga
Thursday Markets Overview
Today we are seeing an across-the-board rise in stock prices on hopes for lower inflation and Omicron jabbing. 
Via Talk Markets
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.